MARKET

MACK

MACK

Merrimack Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.72
+0.15
+2.28%
Opening 10:54 03/08 EST
OPEN
6.73
PREV CLOSE
6.57
HIGH
6.75
LOW
6.68
VOLUME
10.16K
TURNOVER
--
52 WEEK HIGH
9.45
52 WEEK LOW
1.490
MARKET CAP
89.92M
P/E (TTM)
-34.6570
1D
5D
1M
3M
1Y
5Y
Merrimack Pharma Has Returned 67.2% Since SmarTrend Recommendation (MACK)
SmarTrend identified an Uptrend for Merrimack Pharma (NASDAQ:MACK) on August 14th, 2020 at $4.18. In approximately 7 months, Merrimack Pharma has returned 67.22% as of today's recent price of $6.99.
Comtex SmarTrend(R) · 6d ago
Knee Bursitis Treatment Market 2021 | Surges Amid Rising Adoption Medication and Surgery Therapy : Market.us
Mar 01, 2021 (WiredRelease via Comtex) -- A recent systematic review report on “Knee Bursitis Treatment Market : Vendors Are Growing Investments In Research...
marketresearch.biz · 03/01 06:35
Fibroblast Growth Factor Receptor 4 Market Size, Growth, Share 2021 Global, Trends, Global Industry Key Players, Regional Forecast To 2026
Feb 22, 2021 (The Expresswire) -- Global Fibroblast Growth Factor Receptor 4 Market 2021 industry research report gives Advancement strategies and plans are...
The Express Wire · 02/23 04:49
Global HR+/HER2- Breast Cancer Market 2020 with (COVID-19) Impact Analysis, Product Type, Application, Key Manufacturers, Regions and Forecast to 2025
Feb 22, 2021 (CDN Newswire via Comtex) -- Global HR+/HER2- Breast Cancer Market 2020 by Company, Type and Application, Forecast to 2025 brings together an...
CDN Newswire · 02/22 19:23
Merrimack Pharma Shares Up 92.8% Since SmarTrend's Buy Recommendation (MACK)
Feb 20, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for Merrimack Pharma (NASDAQ:MACK) on August 14th, 2020 at $4.18. In...
marketwatch.com · 02/20 09:52
Global Fibroblast Growth Factor Receptor 4 Market Size 2021-2026 With Top Countries Data Industry Price Trend, Size Estimation, Business Growth, Report Latest Research, Business Analysis and Forecast Analysis Research | With Covid 19 Analysis
Feb 19, 2021 (The Expresswire) -- “Fibroblast Growth Factor Receptor 4 Market” Report (2021-2026) offers a learned and top to bottom investigation on the...
The Express Wire · 02/19 05:13
NVAX, APPN, CNDT and MACK among after-hours movers
Gainers: [[CASA]] +25.2%. [[TA]] +8.2%. [[NVAX]] +6.9%. [[AXTI]] +5.5%. [[MACK]] +5%.Losers: [[RXT]] -11.8%. [[CNDT]] -8.3%. [[EHTH]] -6.3%. [[APPN]] -5.4%. [[CENX]] -4%.
Seekingalpha · 02/18 22:46
TWLO, RIGL, ONTX and MACK among premarket gainers
Greenland Technologies Holding Corporation (GTEC) +186% on signing co-operation agreement with SOCMA.Immunome (IMNM) +152% on discovery of antibodies neutralizing SARS-CoV-2 variants.Avinger (AVGR) +57%.Heritage Global (HGBL) +42%.U.S. Well Services (USWS)...
Seekingalpha · 02/18 13:26
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MACK. Analyze the recent business situations of Merrimack Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MACK stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 71
Institutional Holdings: 9.26M
% Owned: 69.20%
Shares Outstanding: 13.38M
TypeInstitutionsShares
Increased
7
348.29K
New
10
719.68K
Decreased
10
78.10K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.16%
Pharmaceuticals & Medical Research
+1.05%
Key Executives
Chairman/President/Treasurer/Director
Gary Crocker
Independent Director
Eric Andersen
Independent Director
Noah Levy
Controller
John Green
Independent Director
Ulrik Nielsen
Independent Director
Russell Ray
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.5007
12/13/2019
07/25/2019
Dividend USD 0
09/06/2019
07/25/2019
Special Dividend USD 1.5
09/06/2019
04/04/2017
Dividend USD 0
05/30/2017
04/04/2017
Special Dividend USD 1.055209
05/30/2017
About MACK
Merrimack Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing novel treatments for cancer by targeting biomarker-defined cancers. Its clinical programs include MM-121 (seribantumab), MM-141 (istiratumab) and MM-310. MM-121 is a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1, or IGF-1, receptor and ErbB3 (HER3) cell surface receptor. MM-310 is an antibody-directed nanotherapeutic that targets the ephrin receptor A2, or EphA2, receptor and contains a novel prodrug of the highly potent chemotherapy docetaxel. The Company’s preclinical programs include MM-161, ATRi, BCL2/BCLxl, TRAIL, Immuno-oncology and STIMULI.

Webull offers kinds of Merrimack Pharmaceuticals Inc stock information, including NASDAQ:MACK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MACK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MACK stock methods without spending real money on the virtual paper trading platform.